Many earlier ctDNA studies in melanoma utilized technologies that target a narrow spectrum of recurrent driver alterations, an approach that limits application in patients with tumors lacking BRAF and NRAS mutations. In contrast, the study successfully identified ctDNA in patients with tumors lacking BRAF and NRAS mutations, suggesting that this tumor-informed approach may be informative in a wider range of patients.
Health Professionals
Dr Doonan on Treatment Strategies Following Progression on ICIs in Advanced Melanoma
Bently P. Doonan, MD, clinical assistant professor, Division of Hematology & Oncology, Department of Medicine, College of Medicine, the University of Florida, discusses current strategies for and associated challenges with the treatment of patients with advanced melanoma following disease progression on immune checkpoint inhibitors (ICIs).
Radioactive Iodine Therapy in Thyroid Cancer May Increase Melanoma Risk
Patients with primary thyroid cancer who received radioactive iodine therapy have elevated risks for melanoma and other nonkeratinocyte skin cancers, according to study findings published in JAMA Network Open.
FDA Grants Fast Track Designation to IMM-1-104 for Advanced Melanoma
The FDA granted a fast track designation to IMM-1-104 (Immuneering Corp.) to treat patients with unresectable or metastatic NRAS-mutant melanoma whose disease progressed or is intolerant to PD-1-/PD-L1-based immune checkpoint inhibitors.1 Currently, the treatment is undergoing evaluation in a phase 2a clinical trial (NCT05585320)2, which enrolled patients with advanced solid tumors, including melanoma.